TIDMOXB
RNS Number : 9918F
Oxford Biomedica PLC
23 May 2017
Oxford BioMedica Annual General Meeting
London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, announces today that all resolutions proposed were
duly passed at its Annual General Meeting (AGM), held today in
London.
In accordance with Listing Rule 9.6.18 the following resolutions
are those which were passed at the meeting concerning special
business:
-- Resolution 7: to authorise the Directors to allot equity
securities for cash, pursuant to section 570 of the Companies Act
2006 as if section 561 of the Companies Act 2006 did not apply to
such allotment, up to an aggregate nominal amount of 5 per cent. of
the presently issued shares;
-- Resolution 8: to empower the Directors to allot equity
securities for cash, pursuant to section 570 of the Companies Act
2006 as if section 561 of the Companies Act 2006 did not apply to
such allotment, up to an aggregate nominal amount of 5 per cent. of
the presently issued shares in connection with an acquisition or
specified capital investment; and
-- Resolution 9: to permit the Directors to convene general
meetings (other than annual general meetings) on not less than 14
days' notice.
The full text of all the resolutions can be viewed in the Notice
of Meeting by visiting the Group's website at
www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above
resolutions passed at the 2017 AGM have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are
shown below. On the Record Date (19 May 2017) there were
3,088,326,065 1p ordinary shares in issue, each carrying one vote
per share.
Votes
Votes at
at other Total
Votes Chairman's proxy Votes Votes votes
Resolution For Discretion Discretion Against Withheld cast Result
------------- --------------- ------------ ------------ ----------- ------------ ---------------- ---------
Ordinary resolutions
1 1,888,465,188 802,799 6,958,793 604,970 398,641 1,897,230,391 Passed
2 1,601,919,465 928,694 6,958,793 4,701,911 282,721,528 1,897,230,391 Passed
3 1,880,264,095 868,254 6,958,793 1,126,450 8,012,799 1,897,230,391 Passed
4 1,880,712,558 872,425 6,958,793 664,300 8,022,315 1,897,230,391 Passed
5 1,813,674,842 880,635 6,958,793 75,322,036 394,085 1,897,230,391 Passed
6 1,887,924,882 925,661 6,958,793 857,070 563,985 1,897,230,391 Passed
Special
resolutions
7 1,774,042,262 1,002,090 6,958,793 1,619,809 113,607,437 1,897,230,391 Passed
8 1,887,104,129 1,002,090 6,958,793 1,557,942 607,437 1,897,230,391 Passed
9 1,879,803,796 1,001,125 6,958,793 9,042,530 424,147 1,897,230,391 Passed
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSEFFDDFWSESI
(END) Dow Jones Newswires
May 23, 2017 09:03 ET (13:03 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024